Frontier Medicines Corporation announced that it has received $80.000001 million in its first tranche from Deerfield Management Company, L.P. Series C, DROIA nv, Galapagos NV, DCVC, MPM Asset Management, L.L.C., RA Capital Management, L.P. and other investors

On February 22, 2024, the company issued 34,196,803 series C preferred stock for gross processed of $80,000,000 in its first tranche. The oversubscribed round of funding was co-led by returning investors DROIA nv and Deerfield Management Company, L.P. The transaction also included participation from new and returning investors including new investor Galapagos NV, returning investors DCVC Bio, L.P., managed by DCVC, MPM Asset Management, L.L.C. and RA Capital Management, L.P. The company has raised $235,500,000 in funding till date.